This may indicate that some types of immunotherapy, such as CTLA-4 and PD-1/PD-L1 blockade as monotherapy, may not be as effective as other cancers with higher mutational loads (e.g., melanoma and non-small cell lung cancer) that tend to respond better. The gene discussed is CTLA4; the disease is cancer.